Journal
INVESTIGATIVE AND CLINICAL UROLOGY
Volume 64, Issue 3, Pages 219-228Publisher
KOREAN UROLOGICAL ASSOC
DOI: 10.4111/icu.20230026
Keywords
Bone neoplasms; Neoplasm metastasis; Prostate cancer
Categories
Ask authors/readers for more resources
The development of novel treatment agents for bone metastatic prostate cancer relies on understanding the underlying mechanisms of metastasis and treatment resistance. Animal models have played a vital role in cancer research, but current models only partially reproduce the process of bone metastasis. Therefore, knowledge of available models and their limitations is crucial for achieving research objectives.
Metastatic disease is a main cause of mortality in prostate cancer and remains to be incurable despite emerging new treatment agents. Development of novel treatment agents are confined within the boundaries of our knowledge of bone metastatic prostate cancer. Exploration into the underlying mechanism of metastatic tumorigenesis and treatment resistance will further expose novel targets for novel treatment agents. Up to date, many of these researches have been conducted with animal models which have served as classical tools that play a pivotal role in understanding the fundamental nature of cancer. The ability to reproduce the natural course of prostate cancer would be of profound value. However, currently available models do not reproduce the entire process of tumorigenesis to bone metastasis and are limited to reproducing small portions of the entire process. Therefore, knowledge of available models and understanding the strengths and weaknesses for each model is key to achieve research objectives. In this article, we take an overview of cell line injection animal models and patient derived xenograft models that have been applied to the research of human prostate cancer bone metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available